Showing results (21-30 of 49) with videos related to
Sort By:
Pageof 5
JAMA Oncology|December 7, 2018
Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP GuidelinesMichael F Press, Jose A Seoane, Christina Curtis, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2011
Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trialWolfgang Eiermann, Tadeusz Pienkowski, John Crown, et al.The Oncologist|August 21, 2025
Intermediate endpoints as surrogates for long term outcomes in breast cancer adjuvant chemotherapy trialsAndrea Blasco, Sara López-Tarruella, Ander Urruticoechea, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2011
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 studyMarco Colleoni, Anita Giobbie-Hurder, Meredith M Regan, et al.The Lancet. Oncology|August 10, 2016
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trialChristoph Zielinski, István Láng, Moshe Inbar, et al.The New England Journal of Medicine|December 29, 2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancerCharles E Geyer, John Forster, Deborah Lindquist, et al.International Journal of Cancer|April 10, 2025
Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studiesJosé A García-Saenz, Gonzalo Spera, Marina Pollán, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2015
PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab ResistanceHoward M Stern, Humphrey Gardner, Tomasz Burzykowski, et al.European Journal of Breast Health|May 29, 2025
What Changes are Mandatory in Breast Surgery Training? An International Survey and Recommendations of the French Academy of Surgery and the Senologic International SocietyTolga Ozmen, Caroline Bouche, Megane Buttignol, et al.Breast Cancer Research : BCR|November 7, 2013
Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysisBella Pajares, Marina Pollán, Miguel Martín, et al.Pageof 5